Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H0N5
UPID:
PHS2_HUMAN
Alternative names:
4-alpha-hydroxy-tetrahydropterin dehydratase 2; DcoH-like protein DCoHm; Dimerization cofactor of hepatocyte nuclear factor 1 from muscle; HNF-1-alpha dimerization cofactor
Alternative UPACC:
Q9H0N5; Q8TD40
Background:
Pterin-4-alpha-carbinolamine dehydratase 2, also known as 4-alpha-hydroxy-tetrahydropterin dehydratase 2, plays a crucial role in tetrahydrobiopterin biosynthesis. It prevents the formation of 7-pterins and accelerates the formation of quinonoid-BH2. Additionally, it regulates the dimerization of homeodomain protein HNF-1-alpha, enhancing its transcriptional activity.
Therapeutic significance:
Understanding the role of Pterin-4-alpha-carbinolamine dehydratase 2 could open doors to potential therapeutic strategies.